Editas Medicine's investment thesis is centered on the high-risk, high-reward potential of its CRISPR gene editing pipeline, but this is fundamentally challenged by a deteriorating financial profile. The company's revenue is erratic and milestone-dependent, wi...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.15+44.5% vs -$0.27 | $12M+317.7% vs $3M |
Q2 2026 May 5, 2026 | -$0.26+13.3% vs -$0.30 | $3M-55.6% vs $6M |
Q2 2026 Mar 9, 2026 | -$0.06+77.8% vs -$0.27 | $25M+196.3% vs $8M |
Q4 2025 Nov 10, 2025 | -$0.28+26.3% vs -$0.38 | $8M-10.8% vs $8M |
Bank of New York Mellon Corp purchased a new position in shares of Editas Medicine, Inc. (NASDAQ: EDIT) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 262,625 shares of the company's stock, valued at approximately $851,000. Bank of New York Mellon Corp owned
Editas Medicine NASDAQ: EDIT outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol.
CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company's newly appointed Chief Medical Officer, Daniel Ory, M.D.
Editas Medicine NASDAQ: EDIT is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O'Neill said during a Wells Fargo discussion.
Benchmark EDIT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Editas Medicine, Inc. (EDIT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.92 | $448.11M | -1.62 | 25.39% | -395.01% | -198.14% | — | |
| $59.03 | $5.69B | -9.12 | -89.97% | -3368.72% | -24.39% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — | |
| $3.35 | $365.8M | -1.67 | — | — | -5.76% | — |
Editas Medicine, Inc. (EDIT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Editas Medicine, Inc. (EDIT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 18, 2026·SEC
May 26, 2026·SEC
Get notified when EDIT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Editas Medicine, Inc. (EDIT) stock FAQ — growth, dividends, profitability & financials explained
Editas Medicine, Inc. (EDIT) reported $47.0M in revenue for fiscal year 2025.
Editas Medicine, Inc. (EDIT) grew revenue by 25.4% over the past year. This is strong growth.
Editas Medicine, Inc. (EDIT) reported a net loss of $73.9M for fiscal year 2025.
Editas Medicine, Inc. (EDIT) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
Editas Medicine, Inc. (EDIT) had negative free cash flow of $120.5M in fiscal year 2025, likely due to heavy capital investments.
